



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

August 2015





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

August 2015

N = 6931



Health Authority	Male	Female	All
FRASER	1307	391	1698
INTERIOR	336	96	432
NORTHERN	139	77	216
VANCOUVER COASTAL	3329	436	3765
VANCOUVER ISLAND	638	149	787
	<b>5749</b>	<b>1149</b>	<b>6898</b>
		<b>Unknown/not stated:</b>	<b>33</b>
		<b>Total:</b>	<b>6931</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2010 - August 2015)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (August 2010 - August 2015)






### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (August 2010 - August 2015)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (August 2010 - August 2015)






### 1.6 Percent Distribution of Active Participants by CD4 Count (August 2010 - August 2015)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (August 2010 - August 2015)






### 1.8 Active and Inactive Participants (August 2010 - August 2015)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (August 2010 - August 2015)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (August 2010 - August 2015)






### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(August 2010 - August 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(August 2010 - August 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(August 2010 - August 2015)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (August 2010 - August 2015)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(August 2010 - August 2015)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (August 2010 - August 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(August 2010 - August 2015)






1.18 Baseline CD4 for Antiretroviral First Starts  
(August 2010 - August 2015)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (August 2010 - August 2015)






1.20 Cumulative Resistance Testing Results by Resistance Category  
(August 2010 - August 2015)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (August 2010 - August 2015)





## 2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	650	5	<40	4
1988	23	8	0	8	8	500	8	<40	4
1989	22	57	2	59	55	500	58	<40	4
1990	21	62	1	63	58	545	61	<40	4
1991	21	39	3	42	36	605	42	<40	4
1992	21	68	5	73	56	570	73	<40	4
1993	20	146	15	161	145	550	158	<40	4
1994	19	98	13	111	91	520	107	<40	4
1995	19	131	26	157	126	525	148	<40	4
1996	17	375	63	438	373	580	423	<40	4
1997	15	315	39	354	312	580	341	<40	3
1998	14	223	48	271	228	560	258	<40	4
1999	14	185	42	227	187	530	215	<40	3
2000	14	140	37	177	151	600	167	<40	3
2001	14	136	37	173	145	570	168	<40	3
2002	13	142	34	176	144	535	170	<40	3
2003	12	176	35	211	181	590	200	<40	3
2004	11	183	47	230	196	570	222	<40	3
2005	10	212	51	263	224	590	253	<40	4
2006	9	217	44	261	213	530	246	<40	3
2007	8	277	56	333	280	580	312	<40	3
2008	7	320	79	399	324	600	374	<40	3
2009	6	349	77	426	361	620	407	<40	3
2010	5	325	76	401	337	630	382	<40	3
2011	4	380	77	457	389	630	434	<40	3
2012	3	317	70	387	327	631	371	<40	3
2013	2	306	72	378	313	590	369	<40	3
2014	1	323	61	384	313	630	371	<40	3
2015	0	253	45	298	268	512	288	<40	4
<b>Total:</b>		<b>5768</b>	<b>1155</b>	<b>6923</b>					

### Definitions:

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	782	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1874	560
MAY-2014	6677	769	2120	<40	1887	560
JUN-2014	6644	784	1994	<40	1768	550
JUL-2014	6682	779	2179	<40	1930	550
AUG-2014	6703	774	2026	<40	1806	570
SEP-2014	6730	770	2284	<40	2003	550
OCT-2014	6760	763	2250	<40	1957	570
NOV-2014	6758	760	1920	<40	1706	580
DEC-2014	6770	766	1896	<40	1688	580
JAN-2015	6746	760	2428	<40	2111	580
FEB-2015	6797	753	1981	<40	1731	570
MAR-2015	6844	747	2174	<40	1890	570
APR-2015	6855	739	2148	<40	1897	580
MAY-2015	6893	739	2030	<40	1778	560
JUN-2015	6906	740	2256	<40	1919	580
JUL-2015	6934	739	2039	<40	1739	580
AUG-2015	6931	750	2078	<40	1682	590

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1410	2265	100	6683	76	285
FEB-2014	1431	2152	73	496	67	490
MAR-2014	1433	2169	114	3726	98	340
APR-2014	1443	2144	112	128	90	400
MAY-2014	1414	2308	90	617	76	350
JUN-2014	1467	2052	96	423	82	380
JUL-2014	1459	2111	95	982	76	355
AUG-2014	1451	2161	87	208	72	365
SEP-2014	1451	2180	103	866	89	390
OCT-2014	1439	2250	84	257	62	395
NOV-2014	1452	2234	74	3945	64	400
DEC-2014	1473	2173	93	557	72	340
JAN-2015	1509	2069	105	1364	85	310
FEB-2015	1490	2140	98	74	84	380
MAR-2015	1463	2308	101	56	89	400
APR-2015	1470	2277	82	2279	66	475
MAY-2015	1454	2376	74	135	60	455
JUN-2015	1473	2305	94	106	88	430
JUL-2015	1467	2352	71	938	54	380
AUG-2015	1482	2303	82	3244	72	425

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1410	2	30	144	136	35	11493
FEB-2014	6548	1431	9	40	139	159	9	11537
MAR-2014	6573	1433	9	36	151	146	25	11581
APR-2014	6587	1443	5	27	159	161	14	11617
MAY-2014	6646	1414	14	38	191	152	59	11667
JUN-2014	6618	1467	7	24	142	183	-28	11705
JUL-2014	6659	1459	8	34	176	159	41	11749
AUG-2014	6683	1451	6	18	165	149	24	11781
SEP-2014	6713	1451	2	25	168	159	30	11820
OCT-2014	6738	1439	7	21	159	146	25	11847
NOV-2014	6732	1452	12	19	135	144	-6	11871
DEC-2014	6745	1473	7	39	136	149	13	11920
JAN-2015	6713	1509	13	24	149	185	-32	11955
FEB-2015	6766	1490	7	36	189	162	53	12007
MAR-2015	6819	1463	7	30	173	141	53	12048
APR-2015	6817	1470	15	28	169	174	-2	12084
MAY-2015	6858	1454	9	33	170	149	41	12125
JUN-2015	6881	1473	5	36	154	162	23	12172
JUL-2015	6921	1467	2	27	165	148	40	12212
AUG-2015	6923	1482	2	19	145	159	2	12242

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6054	424	70	<b>6598</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6067	422	76	<b>6611</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	47	6138	418	74	<b>6677</b>	0.70%	91.93%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	50	6107	416	71	<b>6644</b>	0.75%	91.92%	6.26%	1.07%	<b>100.00%</b>
JUL-2014	47	6147	415	73	<b>6682</b>	0.70%	91.99%	6.21%	1.09%	<b>100.00%</b>
AUG-2014	47	6170	414	72	<b>6703</b>	0.70%	92.05%	6.18%	1.07%	<b>100.00%</b>
SEP-2014	50	6185	424	71	<b>6730</b>	0.74%	91.90%	6.30%	1.05%	<b>100.00%</b>
OCT-2014	45	6208	434	73	<b>6760</b>	0.67%	91.83%	6.42%	1.08%	<b>100.00%</b>
NOV-2014	47	6217	424	70	<b>6758</b>	0.70%	91.99%	6.27%	1.04%	<b>100.00%</b>
DEC-2014	45	6230	421	74	<b>6770</b>	0.66%	92.02%	6.22%	1.09%	<b>100.00%</b>
JAN-2015	47	6185	440	74	<b>6746</b>	0.70%	91.68%	6.52%	1.10%	<b>100.00%</b>
FEB-2015	45	6228	451	73	<b>6797</b>	0.66%	91.63%	6.64%	1.07%	<b>100.00%</b>
MAR-2015	45	6296	436	67	<b>6844</b>	0.66%	91.99%	6.37%	0.98%	<b>100.00%</b>
APR-2015	44	6308	436	67	<b>6855</b>	0.64%	92.02%	6.36%	0.98%	<b>100.00%</b>
MAY-2015	47	6346	432	68	<b>6893</b>	0.68%	92.06%	6.27%	0.99%	<b>100.00%</b>
JUN-2015	49	6338	447	72	<b>6906</b>	0.71%	91.78%	6.47%	1.04%	<b>100.00%</b>
JUL-2015	45	6368	454	67	<b>6934</b>	0.65%	91.84%	6.55%	0.97%	<b>100.00%</b>
AUG-2015	45	6369	446	71	<b>6931</b>	0.65%	91.89%	6.43%	1.02%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3896 59%	19 79%	4269 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3874 59%	37 76%	4246 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3850 59%	25 71%	4214 64%
FEB-2015	8 15%	2594 39%	8 15%	2229 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3887 59%	44 85%	4250 64%
MAR-2015	11 27%	2613 39%	11 27%	2256 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 73%	3920 59%	30 73%	4276 64%
APR-2015	10 29%	2629 40%	10 29%	2270 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3919 59%	24 69%	4275 64%
MAY-2015	8 20%	2641 40%	7 18%	2283 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3933 59%	33 83%	4287 64%
JUN-2015	10 21%	2636 39%	10 21%	2290 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3949 59%	37 79%	4300 64%
JUL-2015	6 15%	2662 40%	6 15%	2316 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 85%	3951 59%	34 85%	4301 64%
AUG-2015	12 40%	2679 40%	11 37%	2338 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3946 59%	18 60%	4287 64%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2075 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2032 60%	18 69%	958 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2047 60%	8 47%	967 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2029 60%	14 67%	983 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2004 59%	6 38%	1013 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1968 58%	10 56%	1030 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	2 13%	1963 58%	11 73%	1044 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1950 58%	7 64%	1050 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1189 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%
APR-2015	4 67%	1149 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1105 43%	0 0%	308 12%	0 0%	879 35%	1 20%	253 10%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	358 19%	0 0%	74 4%	2 8%	881 48%	0 0%	1 0%
MAR-2015	10 53%	602 32%	5 26%	369 20%	0 0%	69 4%	4 21%	870 47%	0 0%	2 0%
APR-2015	7 50%	631 33%	4 29%	374 20%	2 14%	67 4%	1 7%	863 45%	0 0%	2 0%
MAY-2015	11 65%	667 34%	4 24%	383 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	713 35%	8 30%	397 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	12 60%	750 37%	4 20%	404 20%	0 0%	71 3%	4 20%	866 42%	0 0%	1 0%
AUG-2015	11 69%	787 38%	4 25%	413 20%	0 0%	70 3%	1 6%	856 41%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2419	35.78	2190	32.40	1008	14.91	192	2.84	73	1.08	878	12.99
NOV-2014	2422	35.84	2159	31.95	1056	15.63	184	2.72	70	1.04	867	12.83
DEC-2014	2398	35.42	2144	31.67	1104	16.31	185	2.73	74	1.09	865	12.78
JAN-2015	2349	34.82	2125	31.50	1138	16.87	179	2.65	74	1.10	881	13.06
FEB-2015	2366	34.81	2112	31.07	1180	17.36	178	2.62	73	1.07	888	13.06
MAR-2015	2401	35.08	2113	30.87	1207	17.64	185	2.70	67	0.98	871	12.73
APR-2015	2393	34.91	2096	30.58	1243	18.13	184	2.68	67	0.98	872	12.72
MAY-2015	2400	34.82	2094	30.38	1279	18.56	178	2.58	68	0.99	874	12.68
JUN-2015	2369	34.30	2078	30.09	1326	19.20	170	2.46	72	1.04	891	12.90
JUL-2015	2377	34.28	2068	29.82	1355	19.54	170	2.45	67	0.97	897	12.94
AUG-2015	2371	34.21	2044	29.49	1386	20.00	167	2.41	71	1.02	892	12.87

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	30	2	5	5	8	8	393
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	27	6	2	3	6	8	380
AUG-2015	19	2	3	4	2	7	400

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10027	2578
FEB-2014	10049	2571
MAR-2014	10062	2557
APR-2014	10092	2560
MAY-2014	10116	2554
JUN-2014	10151	2564
JUL-2014	10163	2552
AUG-2014	10212	2586
SEP-2014	10254	2596
OCT-2014	10276	2604
NOV-2014	10307	2626
DEC-2014	10348	2630
JAN-2015	10390	2660
FEB-2015	10436	2667
MAR-2015	10475	2675
APR-2015	10495	2687
MAY-2015	10549	2711
JUN-2015	10635	2758
JUL-2015	10707	2804
AUG-2015	10793	2873

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
August 2015

N = 6931

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY











3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

August 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	10
	50+	18	28	12
	<b>Total HSDA:</b>	<b>31</b>	<b>43</b>	<b>22</b>
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	3	3	0
	35-49	18	24	13
	50+	45	60	35
	<b>Total HSDA:</b>	<b>67</b>	<b>88</b>	<b>49</b>
OKANAGAN	0-19	3	3	1
	20-34	20	21	16
	35-49	93	108	69
	50+	191	274	146
	<b>Total HSDA:</b>	<b>307</b>	<b>406</b>	<b>232</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	16	16	11
	35-49	55	69	43
	50+	89	128	74
	<b>Total HSDA:</b>	<b>166</b>	<b>219</b>	<b>129</b>
<b>Total HA:</b>		<b>571</b>	<b>756</b>	<b>432</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	3
	20-34	39	40	27
	35-49	179	216	135
	50+	343	490	267
<b>Total HA:</b>		<b>571</b>	<b>756</b>	<b>432</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	442	598	336
Female	129	158	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	432	52	540	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	8	7
	<b>Total HSDA:</b>	<b>31</b>	<b>22</b>
KOOTENAY BOUNDARY	10 years or more	31	21
	5 years or more	18	14
	<5 years	18	14
	<b>Total HSDA:</b>	<b>67</b>	<b>49</b>
OKANAGAN	10 years or more	164	119
	5 years or more	76	57
	<5 years	67	56
	<b>Total HSDA:</b>	<b>307</b>	<b>232</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	84	58
	5 years or more	35	34
	<5 years	47	37
	<b>Total HSDA:</b>	<b>166</b>	<b>129</b>
<b>Total HA:</b>		<b>571</b>	<b>432</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	295	208
	5 years or more	136	110
	<5 years	140	114
<b>Total HA:</b>		<b>571</b>	<b>432</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	34	46	12	19
KOOTENAY BOUNDARY	59	106	25	40
OKANAGAN	189	641	70	225
THOMPSON/CARIBOO/SHUSWAP	122	405	42	105
<b>Total:</b>	<b>404</b>	<b>1198</b>	<b>149</b>	<b>389</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	41
THOMPSON/CARIBOO/SHUSWAP	37
<b>Total:</b>	<b>91</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	24	25	18
	35-49	123	134	97
	50+	163	222	132
	<b>Total HSDA:</b>	<b>317</b>	<b>388</b>	<b>253</b>
FRASER NORTH	0-19	20	20	5
	20-34	108	109	94
	35-49	360	412	264
	50+	443	688	366
	<b>Total HSDA:</b>	<b>931</b>	<b>1229</b>	<b>729</b>
FRASER SOUTH	0-19	13	13	6
	20-34	93	95	73
	35-49	357	406	298
	50+	405	598	339
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>868</b>	<b>1113</b>	<b>716</b>
<b>Total HA:</b>		<b>2116</b>	<b>2730</b>	<b>1698</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	40	40	17
	20-34	225	229	185
	35-49	840	952	659
	50+	1011	1508	837
	Unknown	0	1	0
<b>Total HA:</b>		<b>2116</b>	<b>2730</b>	<b>1698</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1598	2093	1307
Female	518	637	391

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1698	49	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	144	111
	5 years or more	90	69
	<5 years	83	73
	<b>Total HSDA:</b>	<b>317</b>	<b>253</b>
FRASER NORTH	10 years or more	440	324
	5 years or more	236	190
	<5 years	255	215
	<b>Total HSDA:</b>	<b>931</b>	<b>729</b>
FRASER SOUTH	10 years or more	390	308
	5 years or more	238	198
	<5 years	240	210
	<b>Total HSDA:</b>	<b>868</b>	<b>716</b>
<b>Total HA:</b>		<b>2116</b>	<b>1698</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	974	743
	5 years or more	564	457
	<5 years	578	498
<b>Total HA:</b>		<b>2116</b>	<b>1698</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	125	391	43	74
FRASER NORTH	223	1352	63	270
FRASER SOUTH	201	1152	51	348
<b>Total:</b>	<b>549</b>	<b>2895</b>	<b>157</b>	<b>692</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	189
FRASER NORTH	614
FRASER SOUTH	485
<b>Total:</b>	<b>1288</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	20	20	16
	35-49	85	99	66
	50+	193	312	167
	<b>Total HSDA:</b>	<b>300</b>	<b>433</b>	<b>249</b>
RICHMOND	0-19	7	7	1
	20-34	21	21	20
	35-49	45	48	38
	50+	73	112	60
	<b>Total HSDA:</b>	<b>146</b>	<b>188</b>	<b>119</b>
VANCOUVER	0-19	57	60	7
	20-34	411	419	321
	35-49	1626	1906	1219
	50+	2338	3871	1850
	<b>Total HSDA:</b>	<b>4432</b>	<b>6256</b>	<b>3397</b>
<b>Total HA:</b>		<b>4878</b>	<b>6877</b>	<b>3765</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	66	69	8
	20-34	452	460	357
	35-49	1756	2053	1323
	50+	2604	4295	2077
<b>Total HA:</b>		<b>4878</b>	<b>6877</b>	<b>3765</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4287	6044	3329
Female	589	831	436

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3765	51	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	165	129
	5 years or more	49	45
	<5 years	86	75
	<b>Total HSDA:</b>	<b>300</b>	<b>249</b>
RICHMOND	10 years or more	68	51
	5 years or more	33	25
	<5 years	45	43
	<b>Total HSDA:</b>	<b>146</b>	<b>119</b>
VANCOUVER	10 years or more	2199	1583
	5 years or more	1096	862
	<5 years	1137	952
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4432</b>	<b>3397</b>
<b>Total HA:</b>	<b>4878</b>	<b>3765</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2432	1763
5 years or more	1178	932
<5 years	1268	1070
Never on ART	0	0
<b>Total HA:</b>	<b>4878</b>	<b>3765</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	136	358	53	87
RICHMOND	41	256	13	87
VANCOUVER	523	9660	204	5217
<b>Total:</b>	<b>700</b>	<b>10274</b>	<b>270</b>	<b>5391</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	1
VANCOUVER	101
<b>Total:</b>	<b>108</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	22	24	17
	35-49	84	98	73
	50+	153	245	123
	<b>Total HSDA:</b>		<b>261</b>	<b>369</b>
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	13	14	7
	35-49	37	41	33
	50+	56	84	46
	<b>Total HSDA:</b>		<b>108</b>	<b>141</b>
SOUTH VANCOUVER ISLAND	0-19	8	8	1
	20-34	41	43	30
	35-49	208	247	162
	50+	372	581	293
	<b>Total HSDA:</b>		<b>629</b>	<b>879</b>
<b>Total HA:</b>		<b>998</b>	<b>1389</b>	<b>787</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	3
	20-34	76	81	54
	35-49	329	386	268
	50+	581	910	462
<b>Total HA:</b>		<b>998</b>	<b>1389</b>	<b>787</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	804	1123	638
Female	194	266	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	787	52	470	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	123	96
	5 years or more	65	54
	<5 years	73	64
	<b>Total HSDA:</b>	<b>261</b>	<b>214</b>
NORTH VANCOUVER ISLAND	10 years or more	47	37
	5 years or more	24	19
	<5 years	37	31
	<b>Total HSDA:</b>	<b>108</b>	<b>87</b>
SOUTH VANCOUVER ISLAND	10 years or more	309	212
	5 years or more	154	126
	<5 years	166	148
	<b>Total HSDA:</b>	<b>629</b>	<b>486</b>
<b>Total HA:</b>		<b>998</b>	<b>787</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	479	345
	5 years or more	243	199
	<5 years	276	243
<b>Total HA:</b>		<b>998</b>	<b>787</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	533	79	176
NORTH VANCOUVER ISLAND	112	230	46	71
SOUTH VANCOUVER ISLAND	180	1496	47	517
<b>Total:</b>	<b>458</b>	<b>2259</b>	<b>172</b>	<b>764</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	45
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	75
<b>Total:</b>	<b>150</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	6	7	4
	35-49	18	20	12
	50+	16	21	10
	<b>Total HSDA:</b>	<b>41</b>	<b>49</b>	<b>26</b>
NORTH WEST	0-19	1	1	0
	20-34	8	12	6
	35-49	28	40	24
	50+	30	45	23
	<b>Total HSDA:</b>	<b>67</b>	<b>98</b>	<b>53</b>
NORTHERN INTERIOR	0-19	5	5	4
	20-34	28	31	21
	35-49	71	86	56
	50+	71	117	56
	<b>Total HSDA:</b>	<b>175</b>	<b>239</b>	<b>137</b>
<b>Total HA:</b>		<b>283</b>	<b>386</b>	<b>216</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	4
	20-34	42	50	31
	35-49	117	146	92
	50+	117	183	89
<b>Total HA:</b>		<b>283</b>	<b>386</b>	<b>216</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	178	246	139
Female	105	140	77

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	216	47	510	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	7
	5 years or more	11	8
	<5 years	15	11
	<b>Total HSDA:</b>	<b>41</b>	<b>26</b>
NORTH WEST	10 years or more	17	8
	5 years or more	22	19
	<5 years	28	26
	<b>Total HSDA:</b>	<b>67</b>	<b>53</b>
NORTHERN INTERIOR	10 years or more	49	31
	5 years or more	48	41
	<5 years	78	65
	<b>Total HSDA:</b>	<b>175</b>	<b>137</b>
<b>Total HA:</b>		<b>283</b>	<b>216</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	81	46
	5 years or more	81	68
	<5 years	121	102
<b>Total HA:</b>		<b>283</b>	<b>216</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	30	56	7	9
NORTH WEST	60	139	19	25
NORTHERN INTERIOR	95	376	23	180
<b>Total:</b>	<b>185</b>	<b>571</b>	<b>49</b>	<b>214</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	23
<b>Total:</b>	<b>49</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	7
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	19	34	18
	<b>Total HA:</b>	<b>44</b>	<b>78</b>	<b>35</b>
FRASER	FRASER EAST	32	40	27
	FRASER NORTH	65	94	51
	FRASER SOUTH	67	93	56
	<b>Total HA:</b>	<b>164</b>	<b>227</b>	<b>134</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	17
	RICHMOND	8	13	7
	VANCOUVER	488	763	404
	<b>Total HA:</b>	<b>518</b>	<b>817</b>	<b>428</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	72	37
	NORTH VANCOUVER ISLAND	13	22	10
	SOUTH VANCOUVER ISLAND	32	69	24
	<b>Total HA:</b>	<b>92</b>	<b>163</b>	<b>71</b>
NORTHERN	NORTH EAST	10	12	6
	NORTH WEST	33	56	29
	NORTHERN INTERIOR	62	92	54
	<b>Total HA:</b>	<b>105</b>	<b>160</b>	<b>89</b>
<b>Total:</b>		<b>923</b>	<b>1445</b>	<b>757</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	587	932	476
Female	336	513	281

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	757	48	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare's trade name for a pill that combines ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

